Abstract 109P
Background
With 18F-FDG PET/CT, tumor uptake intensity and textural features have been associated with outcome in several types of cancer. This study was to evaluate the prognostic value of pretreatment 18F-FDG PET/CT textural parameters in patients with primary metastatic colorectal cancer (CRC).
Methods
All patients (n = 104) who had had a pretreatment image of 18F-FDG PET/CT at our Hospital from January 2009 to December 2015 were included. Volumes of interest (VOIs) were drawn freehand around the tumor, and texture analysis was conducted on both CT and PET images within the same VOIs. A total of 35 features were extracted and analyzed. Univariate and multivariate analyses (logistic regression) were conducted to assess the prognostic value of textural parameters. Moreover, radiomics score (rad-score) was constructed using logistic regression. A multivariate logistic regression model was then used to establish a nomogram including the rad-score and other clinicopathological features.
Results
The results of univariate analysis showed that 18 textural parameters such as skewness and kurtosis were significantly associated with survival. In multivariate model, 17 textural parameters were shown to be able to predict PFS, including skewness (HR 2.777, p < 0.001), kurtosis (HR 0.441, p < 0.001), entropy (HR 1.704, p = 0.014), homogeneity (HR 0.548, p = 0.006), SRE (HR 1.853, p = 0.005), LRE (HR, p = 0.005), HGRE (HR 1.616, p = 0.036), LZE (HR 0.597, p = 0.018), LGZE (HR 0.439, p < 0.001) and HGZE (HR 2.085, p = 0.001). In addition, 8 textural parameters such as skewness (HR 4.475, p < 0.001), kurtosis (HR 0.377, p < 0.001), SRHGE (HR 2.062, p = 0.005) and LRLGE (HR 0.475, p = 0.003), were revealed to be independent predictors of OS among our population.
Conclusions
The texture analysis of the baseline 18F-FDG PET/CT appears to be a potential tool to predict outcomes of patients with primary metastatic CRC. However, prospective studies with a large population are needed to confirm the present findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract